Article
Pharmacology & Pharmacy
Han Liu, Peng Chen, Yong-Long Yang, Ke-Wei Zhu, Tao Wang, Ling Tang, Yan-Ling Liu, Shan Cao, Gan Zhou, Hui Zeng, Xie-Lan Zhao, Wei Zhang, Xiao-Ping Chen
Summary: The study identified TBC1D16 as a potential predictor for chemosensitivity and prognosis in adult AML patients, with higher methylation and expression of this gene associated with increased risk of incomplete remission and worse overall survival.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Oncology
Tianxin Lyu, Yinuo Wang, Ding Li, Hui Yang, Bin Qin, Wenli Zhang, Zhiyue Li, Cheng Cheng, Binglei Zhang, Rongqun Guo, Yongping Song
Summary: This study revealed that BM-MSC-exos increased the metastatic potential, maintained stemness, and contributed to chemoresistance of leukemia cells by upregulating S100A4. Downregulation of S100A4 suppressed proliferation, invasion, and chemoresistance of leukemia cells, indicating its potential as a therapeutic target in leukemia. Bioinformatic analysis from TCGA database showed S100A4's association with poor prognosis in AML patients and its involvement in cell-cell adhesion and cytokine regulation processes.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2021)
Article
Oncology
Jianle Lu, Qiaomei Dong, Shuling Zhang, Youfan Feng, Jincai Yang, Li Zhao
Summary: Acute myeloid leukemia (AML) is often resistant to treatment, and the presence of mesenchymal stem cells (MSCs) in the leukemia microenvironment contributes to this resistance. In this study, AML-MSCs were found to induce a mesenchymal-like morphology in drug-resistant AML cells and promote their growth in vitro and in vivo. The mechanism underlying this induction involved the secretion of interleukin-6 (IL-6) by AML-MSCs, which activated the JAK2/STAT3 pathway in AML cells. This study highlights the role of AML-MSCs in promoting chemoresistance and provides a potential therapeutic target for reversing resistance in AML.
Article
Hematology
Sofia von Palffy, Hanna Thorsson, Pablo Pena-Martinez, Noelia Puente-Moncada, Carl Sanden, Anna M. Blom, Rasmus Henningsson, Gunnar Juliusson, Ben King, Niklas Landberg, Vladimir Lazarevic, Christina Orsmark-Pietras, Marianne Rissler, Vendela Rissler, Helena Agerstam, Marcus Jaras, Henrik Lilljebjorn, Thoas Fioretos
Summary: Mutations in the NPM1 gene are common in acute myeloid leukemia (AML), but relapse is still a significant concern. In this study, we identified the complement receptor C3AR as specifically expressed in NPM1-mutated AML cells, making it a potential target for antibody-based therapies. We also found that C3AR, in combination with GPR56, distinguishes leukemic stem cells from normal hematopoietic stem cells, and stimulation of C3AR-expressing cells leads to increased survival of AML cells. Furthermore, antibodies directed against C3AR effectively induce natural killer cell-mediated killing of primary AML cells, highlighting its potential as a therapeutic target in NPM1-mutated AML.
Article
Cell Biology
Meng Li, Mingying Li, Yuan Xia, Guosheng Li, Xiuhua Su, Dongmei Wang, Jingjing Ye, Fei Lu, Tao Sun, Chunyan Ji
Summary: The study revealed that YY1 binds to the promoter region of METTL3 as a transcription factor and regulates METTL3 expression through LLPS, thereby affecting the proliferation of AML cells.
CELL DEATH & DISEASE
(2022)
Article
Immunology
Lakshmi Sandhow, Huan Cai, Elory Leonard, Pingnan Xiao, Luana Tomaipitinca, Alma Mansson, Makoto Kondo, Xiaoyan Sun, Anne-Sofie Johansson, Karl Tryggvason, Maria Kasper, Marcus Jaras, Hong Qian
Summary: This study demonstrates the regenerative capacity of AML cells infiltrated in the skin and the role of skin mesenchymal niches in maintaining and protecting AML cells. It provides new insight into the pathology of leukemia cutis and suggests potential implications for AML relapse.
JOURNAL OF EXPERIMENTAL MEDICINE
(2023)
Review
Oncology
Ying-Jun Chang, Xiang-Yu Zhao, Xiao-Jun Huang
Summary: Haploidentical stem cell transplantation is an effective alternative donor source for AML patients, with outcomes comparable to traditional transplantation methods for various types of AML. Relapse and infections post haplo-SCT remain key challenges in improving clinical outcomes for AML patients. Areas of active research include relapse prophylaxis, intervention, treatment, as well as infection prevention and therapy.
FRONTIERS IN ONCOLOGY
(2021)
Editorial Material
Oncology
Alexander E. Perl, Paresh Vyas
Summary: Two publications provide new insights into risk stratification in patients with acute myeloid leukemia and mutations in IDH1, IDH2, or FLT3 who received initial therapy with venetoclax and azacitidine, setting the stage for future trials integrating molecularly targeted therapy with this new standard regimen.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Thais Oliveira, Douglas Lemos, Louise Jean, Jessica M. Kawashima, Vitoria R. de Azevedo, Eduardo J. Salustiano, Vivian M. Rumjanek, Robson Q. Monteiro
Summary: This study found that disrupting the hexokinase II in multidrug resistant cells of chronic myeloid leukemia can impair bioenergetic parameters, increase drug accumulation, and induce cell death. This could be a promising strategy for the management of chemotherapy-refractory patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Arvind Singh Mer, Emily M. Heath, Seyed Ali Madani Tonekaboni, Nergiz Dogan-Artun, Sisira Kadambat Nair, Alex Murison, Laura Garcia-Prat, Liran Shlush, Rose Hurren, Veronique Voisin, Gary D. Bader, Corey Nislow, Mattias Rantalainen, Soren Lehmann, Mark Gower, Cynthia J. Guidos, Mathieu Lupien, John E. Dick, Mark D. Minden, Aaron D. Schimmer, Benjamin Haibe-Kains
Summary: The molecular heterogeneity of AML poses challenges for prognosis and therapy. NPM1 mutated AML is heterogeneous, with two subtypes exhibiting distinct molecular characteristics, differentiation state, patient survival, and drug response.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Po-Liang Cheng, Tzu-Hung Hsiao, Chung-Hsing Chen, Miao-Neng Hung, Pei-Pei Jhan, Li-Wen Lee, Ting-Shuan Wu, Jia-Rung Tsai, Chieh-Lin Jerry Teng
Summary: This study aimed to identify potential mechanisms of chemoresistance of the 7 + 3 induction in acute myeloid leukemia (AML) cells using a single-cell RNA sequencing (scRNA-seq) approach. The results showed that chemoresistant AML cells had premature accumulation during early hematopoiesis and expressed more leukemic stem cell markers than chemosensitive cells. In addition, patients with higher expression of chemoresistant genetic markers had worse overall survival.
HEMATOLOGICAL ONCOLOGY
(2023)
Review
Hematology
Asiri Ediriwickrema, Andrew J. Gentles, Ravindra Majeti
Summary: The era of genomic medicine has advanced AML research, but AML remains a lethal cancer due to its complex and plastic cellular architecture. Single-cell genomics has the potential to address the challenges posed by cellular heterogeneity and provide unique opportunities in AML research.
Article
Hematology
Sridevi Surapally, Daniel G. Tenen, John A. Pulikkan
Summary: This review focuses on the key role of CBF beta-SMMHC in AML and recent advances in therapeutic strategies targeting CBF beta-SMMHC in inv(16) AML.
Review
Oncology
Naval Daver, Ahmad S. Alotaibi, Veit Bucklein, Marion Subklewe
Summary: AML is a heterogeneous disease with a broad spectrum of molecular abnormalities, requiring multiple therapeutic approaches for long-term disease control. Recent advancements in understanding and targeting these molecular aberrations have led to rapid evolution in AML treatment, with a focus on immunotherapies harnessing T cells. Multiple T-cell-based immunotherapies, including bispecific antibodies, CAR T-cell therapies, and immune checkpoint inhibitors, are in various stages of development for AML treatment.
Article
Immunology
Roberto Limongello, Andrea Marra, Antonella Mancusi, Samanta Bonato, Eni Hoxha, Loredana Ruggeri, Susanta Hui, Andrea Velardi, Antonio Pierini
Summary: Adverse genetic risk acute myeloid leukemia (AML) poses a significant treatment challenge with poor outcomes, necessitating novel therapeutic approaches. While allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the curative option, high relapse rates and dismal outcomes prompt the exploration of new transplant strategies. Recent research has shown that haploidentical allo-HSCT combined with T cell adoptive immunotherapy can overcome chemoresistance and improve survival in AML patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Sheng Li, Francine E. Garrett-Bakelman, Stephen S. Chung, Mathijs A. Sanders, Todd Hricik, Franck Rapaport, Jay Patel, Richard Dillon, Priyanka Vijay, Anna L. Brown, Alexander E. Perl, Joy Cannon, Lars Bullinger, Selina Luger, Michael Becker, Ian D. Lewis, Luen Bik To, Ruud Delwel, Bob Lowenberg, Hartmut Doehner, Monica L. Guzman, Duane C. Hassane, Gail J. Roboz, David Grimwade, Peter J. M. Valk, Richard J. D'Andrea, Martin Carroll, Christopher Y. Park, Donna Neuberg, Ross Levine, Ari M. Melnick, Christopher E. Mason
Article
Multidisciplinary Sciences
Francois Bordeleau, Brooke N. Mason, Emmanuel Macklin Lollis, Michael Mazzola, Matthew R. Zanotelli, Sahana Somasegar, Joseph P. Califano, Christine Montague, Danielle J. LaValley, John Huynh, Nuria Mencia-Trinchant, Yashira L. Negron Abril, Duane C. Hassane, Lawrence J. Bonassar, Jonathan T. Butcher, Robert S. Weiss, Cynthia A. Reinhart-King
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2017)
Review
Hematology
N. M. Cruz, N. Mencia-Trinchant, D. C. Hassane, M. L. Guzman
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2017)
Article
Medicine, Research & Experimental
Utthara Nayar, Jouliana Sadek, Jonathan Reichel, Denise Hernandez-Hopkins, Gunkut Akar, Peter J. Barelli, Michelle A. Sahai, Hufeng Zhou, Jennifer Totonchy, David Jayabalan, Ruben Niesvizky, Ilaria Guasparri, Duane Hassane, Yifang Liu, Shizuko Sei, Robert H. Shoemaker, J. David Warren, Olivier Elemento, Kenneth M. Kaye, Ethel Cesarman
JOURNAL OF CLINICAL INVESTIGATION
(2017)
Article
Pathology
Nuria Mencia-Trinchant, Yang Hu, Maria Antonina Alas, Fatima Ali, Bas J. Wouters, Sangmin Lee, Ellen K. Ritchie, Pinkal Desai, Monica L. Guzman, Gail J. Roboz, Duane C. Hassane
JOURNAL OF MOLECULAR DIAGNOSTICS
(2017)
Article
Oncology
John N. Allan, Gail J. Roboz, Gulce Askin, Ellen Ritchie, Joseph Scandura, Paul Christos, Duane C. Hassane, Monica L. Guzman
LEUKEMIA & LYMPHOMA
(2018)
Article
Pathology
Julia T. Geyer, Wayne Tam, Yen-Chun Liu, Zhengming Chen, Sa A. Wang, Carlos Bueso-Ramos, Jean Oak, Daniel A. Arber, Eric Hsi, Heesun J. Rogers, Katherine Levinson, Adam Bagg, Duane C. Hassane, Robert P. Hasserjian, Attilio Orazi
Article
Oncology
Jacob L. Glass, Duane Hassane, Bas J. Wouters, Hiroyoshi Kunimoto, Roberto Avellino, Francine E. Garrett-Bakelman, Olga A. Guryanova, Robert Bowman, Shira Redlich, Andrew M. Intlekofer, Cem Meydan, Tingting Qin, Mame Fall, Alicia Alonso, Monica L. Guzman, Peter J. M. Valk, Craig B. Thompson, Ross Levine, Olivier Elemento, Ruud Delwel, Ari Melnick, Maria E. Figueroa
Article
Hematology
Duane C. Hassane, Siddhartha Sen, Mohammad Minhajuddin, Randall M. Rossi, Cheryl A. Corbett, Marlene Balys, Liping Wei, Peter A. Crooks, Monica L. Guzman, Craig T. Jordan
Article
Cell & Tissue Engineering
John M. Ashton, Marlene Balys, Sarah J. Neering, Duane C. Hassane, Glenn Cowley, David E. Root, Peter G. Miller, Benjamin L. Ebert, Helene R. McMurray, Hartmut Land, Craig T. Jordan
Article
Hematology
Siddhartha Sen, Duane C. Hassane, Cheryl Corbett, Michael W. Becker, Craig T. Jordan, Monica L. Guzman
EXPERIMENTAL HEMATOLOGY
(2013)
Article
Oncology
Monica L. Guzman, Neng Yang, Krishan K. Sharma, Marlene Balys, Cheryl A. Corbett, Craig T. Jordan, Michael W. Becker, Ulrich Steidl, Omar Abdel-Wahab, Ross L. Levine, Guido Marcucci, Gail J. Roboz, Duane C. Hassane
MOLECULAR CANCER THERAPEUTICS
(2014)
Article
Biochemistry & Molecular Biology
E. R. Sampson, H. R. McMurray, D. C. Hassane, L. Newman, P. Salzman, C. T. Jordan, H. Land
Article
Oncology
Richard T. Silver, Ariella C. Barel, Elena Lascu, Ellen K. Ritchie, Gail J. Roboz, Paul J. Christos, Attilio Orazi, Duane C. Hassane, Wayne Tam, Nicholas C. P. Cross
Review
Oncology
Xinru Zhou, Yin Jia, Chuanbin Mao, Shanrong Liu
Summary: Small extracellular vesicles (sEVs), such as exosomes, have emerged as crucial targets for liquid biopsy and promising drug delivery vehicles in tumor progression. They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatment.
Article
Oncology
Ruochan Chen, Ju Zhu, Xiao Zhong, Jie Li, Rui Kang, Daolin Tang
Summary: The interplay between autophagy and apoptosis plays a crucial role in tumorigenesis and cancer therapy, with HMGB1 serving as a key regulator in these processes.
Article
Oncology
Zongfu Pan, Xixuan Lu, Tong Xu, Jinming Chen, Lisha Bao, Ying Li, Yingying Gong, Yulu Che, Xiaozhou Zou, Zhuo Tan, Ping Huang, Minghua Ge
Summary: This study uncovered the emerging role of HN1 in promoting dedifferentiation of anaplastic thyroid cancer (ATC) cells. HN1 negatively regulated the thyroid differentiation markers and had an inhibitory effect on the transcriptional activation of CTCF, thereby influencing the chromatin accessibility of thyroid differentiation genes.
Article
Oncology
Yi Qin, Shengjun Xiong, Jun Ren, Gautam Sethi
Summary: Autophagy plays an important regulatory role in glioblastoma, and its dysregulation can lead to drug resistance and radioresistance. It also affects stem cell characteristics, overall growth, and metastasis. Therefore, autophagy is a promising target for glioblastoma therapy.
Article
Oncology
Katsuya Nagaoka, Xuewei Bai, Dan Liu, Kevin Cao, Joud Mulla, Chengcheng Ji, Hongze Chen, Muhammad Azhar Nisar, Amalia Bay, William Mueller, Grace Hildebrand, Jin-Song Gao, Shaolei Lu, Hiroko Setoyama, Yasuhito Tanaka, Jack R. Wands, Chiung-Kuei Huang
Summary: This study found that serum 2-OG levels in cholangiocarcinoma patients are associated with the effectiveness of chemotherapy. Patients with progressive disease showed significantly higher levels of serum 2-OG compared to stable disease and partial response patients. The study also revealed that overexpression of ASPH mimics the effects of 2-OG, and knockdown of ASPH improves chemotherapy. Targeting ASPH enhances the effects of chemotherapy by modulating ATM and ATR, two key regulators of DDRs.
